Celestra Inc (352770)

Celestra Inc., a biotechnology company, provides genome-based cancer and disease diagnostic solutions. It provides TrioDx RT-PCR COVID-19 Test (FDA EUA), liquid biopsy and precision medicines, health care services, and big data solutions. The company’s liquid biopsy and precision medicines include CD-PRIME, a platform that offers automated protocols for the enrichment of circulating tumor cells (CTCs), cell free DNA, and EV (exosome) derived from cancer tissues; Cancer-PRIME, a cancer gene analysis service for analyzing results related to precision medicine information with bioinformatics and the detection of various gene mutations; and BioViewCCBS, a scanning platform that helps in capturing cells inside the sample in 3D and in finding and analyzing CTC inside the sample. It also acts as the distributor and seller for AmoyDx’s molecule diagnosis method kit in Korea, which is a diagnostics kit used to predict NSCLC patients’ reactions to specific drug treatment; for Fluxion Biosciences’ Spotlight 59 Panel that provides sensitive detection result with a design for mutated cell detection in cancer samples; and for Fluxion Biosciences’ IsoFlux System, an analysis system for circulating tumor cells to extract rare cells to be used in the desired field of applications. In addition, the company provides health care services, such as Geno-P, which provides specialized genome information for 11 physical characteristics based on genome standard reference data; Geno-D that provides prediction services for probability of incidence of diseases; GenomeBook, which provides whole genome information; NIP10, an examination service that is possible after 10 weeks of pregnancy through non-invasive, pre-birth examination to detect fetal chromosome abnormalities; and biological age analysis service. Further, it provides BioComputer, which is an automated computing infrastructure solution to process genomic data. The company was founded in 2011 and is based in Ulsan, South Korea.